Is global elimination of HCV realistic?

Abstract

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6‐10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of knowledge in the epidemiology of HCV and what can be done to increase patient awareness and reduce the barriers to treatment. Furthermore, we will discuss the role of HCV clearance on the control of HCV‐related outcomes.

 

KEYWORDS
direct antiviral agents, linkage to care, screening

 

About Speaker

Antonio CRAXI

Professor of Gastroenterology and Internal Medicine

Italy

City: Palermo

Institution: University of Palermo

Contact: antonio.craxi@unipa.it


Biography of Antonio CRAXI

Antonio Craxì is Full Professor of Gastroenterology and Internal Medicine at the University of Palermo, Palermo, Italy, where he is also Director of Gastroenterology and Hepatology at the University’s Academic Department of Internal Medicine. He obtained his medical degree from the University of Palermo and trained in gastroenterology at the University of Rome. Following this, he was a Research Fellow at the Royal Free Hospital, London, UK. Professor Craxì’s main research interests range from pathobiology of hepatitis B and C to antiviral therapy, nonalcoholic steatohepatitis, hepatocellular carcinoma and the natural history and epidemiology of chronic liver disease. He is a member of the AASLD, EASL, the Italian Association for the Study of the Liver (AISF) and the International Liver Cancer Association (ILCA). Among the contributions to the hepatology arena are more than 250 full papers published in international journals, and presentations at both national and international meetings. He serves, or has served, on the editorial boards for several leading journals, including Hepatology, Journal of Hepatology, Current Opinions in Hepatology, World Journal of Gastroenterology, Viral Hepatitis Reviews and Hepatology Reviews.

View more